Uncategorized
Fortrea CEO Steps Down Amid Continued Stock Decline Post-Labcorp Spinout
Fortrea; Labcorp; CEO departure; stock decline; CRO spinout; leadership change; clinical trials; public company
White House Threatens Most Favored Nation Plan to Lower US Drug Prices, but Many Questions Remain
Most Favored Nation; drug pricing; White House; executive order; prescription drugs; Trump administration; US drug prices; global price comparison; pharmaceutical policy
Trump’s Drug Pricing Order Raises Questions of Effectiveness
Trump; Drug Pricing; Executive Order; Most-Favored-Nation Pricing
Where AI Adds Real Value in Clinical Development: 2025 Insights
AI in clinical development; clinical trials; drug discovery; protocol design; patient recruitment; data analysis; regulatory compliance
Roche Pledges Nearly $300M to Establish New Vabysmo Production Plant in China
Roche; Vabysmo; biopharmaceutical manufacturing; Shanghai; China; investment; eye disease treatment; plant construction; localization; green energy
Roche injects $550M into Indianapolis hub to scale up CGM production
Indianapolis, Roche (company), Continuous glucose monitoring, production, Manufacture, Investments, United States
Fierce Biotech Layoff Tracker 2025: 10x Genomics cuts 8% of global workforce; NGM sheds 75% of staff
NGM, Genomics, Fierce, 8, Generalized, Staff, 75%, 2025
Chronic care startup Omada Health files to go public
Chronic care management, virtual care, IPO, digital health, diabetes management, cardiometabolic health, hypertension, musculoskeletal conditions, revenue growth, Hinge Health
Roche could rethink $50B US expansion plan if new policies ‘harm’ operations
Roche (company), United States, Investments, expansion, Policy, Infantile Neuroaxonal Dystrophy
Lilly says further head-to-head trial data back Zepbound over Novos Wegovy
Tirzepatide, Semaglutide, Weight Loss, Obesity Treatment, SURMOUNT-5 Trial, Comparative Efficacy